Alyftrek access in India: the CDSCO named-patient pathway
How India patients legally obtain Alyftrek (vanzacaftor / tezacaftor / deutivacaftor) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Alyftrek in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in India access Alyftrek (vanzacaftor-tezacaftor-deutivacaftor) for cystic fibrosis with responsive mutations through the CDSCO Rule 36 personal-import authorisation, a federal mechanism that allows a treating Indian physician to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Alyftrek reaches patients in India
Alyftrek (vanzacaftor / tezacaftor / deutivacaftor, a next-generation oral CFTR triple combination from Vertex Pharmaceuticals, FDA-approved 20 December 2024 for cystic fibrosis in patients aged 6 years and older with at least one F508del mutation or another responsive CFTR mutation, label resource at accessdata.fda.gov) is not visible on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. India patients access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945, read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. Applications are filed online via the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. We give you a written timeline estimate for your case before you commit. When a tertiary CF centre files on behalf of an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The application requires a registered medical practitioner's prescription with National Medical Commission registration number, drug strength and quantity, and the patient's case summary. Form 12-B permits are single-consignment; chronic-therapy families re-file at each shipment cycle.
Where Alyftrek is dispensed in India
Alyftrek is an oral once-daily tablet taken with fat-containing food and dispensed in outpatient CF specialty clinic settings with sweat-chloride monitoring, lung function (ppFEV1) surveillance, hepatic enzyme baseline and routine LFTs, and paediatric ophthalmology screening. The Cystic Fibrosis Foundation of India operates an informal national network through these centres. The dispensing facility must hold a drug licence covering imported unregistered medicines.
What Alyftrek costs in India
Medicine price: quote on request. Every case gets a written custom quote before you commit. Paediatric patients aged 6 to less than 12 years receive weight-banded dosing per the FDA-approved label. Cost layers stacked on drug cost include international ambient or refrigerated freight depending on the lane (Alyftrek tablets are stable at controlled room temperature per the FDA label), CDSCO permit and customs handling, the dispensing facility's drug-handling fee, and the Reserve Meds coordination fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines is 5 percent. Re-supply cadence is quarterly for many families after the first cycle is stable.
Funding and access barriers for Alyftrek in India
The cap is structured around one-time or short-course treatments and is not naturally aligned with indefinite CFTR-modulator dosing at originator pricing. Medicine price: quote on request. You get a written quote for your case before you commit. private health insurers assess unregistered named-patient imports case by case; IRDAI has not issued a uniform rule for this category. The dominant funding pattern for an Alyftrek case is family self-pay supplemented by diaspora remittance, crowdfunding through Ketto, Milaap, and ImpactGuru, and the Vertex GPS (Guidance & Patient Support) compassionate-access programme where the company operates one in the patient's home country. CFTR-modulator access in India has been the subject of patient-advocacy lobbying and Delhi High Court petitions; the Cystic Fibrosis Society of India tracks developments. Foreign Contribution (Regulation) Act 2010 considerations may apply where a foreign foundation is the named donor.
Recent regulatory and access news for Alyftrek
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not published an Alyftrek-specific notification over the last 12 months as of 2026-06-01. The Ministry of Health and Family Welfare continues quarterly Health Minister's Committee updates on the NPRD 2021 Centres of Excellence and disease coverage at mohfw.gov.in, with no Alyftrek-specific reclassification observed in the most recent roster. Indian patient-advocacy organisations including the Cystic Fibrosis Society of India have continued advocacy for broader CFTR-modulator access through 2025 and 2026, with public reporting of compassionate-access negotiations between Vertex and Indian institutions. India-specific Alyftrek registration filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.
Where Reserve Meds fits in Alyftrek cases
Reserve Meds is a US-based digital health company. We do not replace your Indian specialist, we do not replace the CDSCO, and we do not replace your dispensing pharmacy. For Alyftrek specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into India, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your Indian physician has prescribed Alyftrek and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.